

**OPTIMA HEALTH COMMUNITY CARE
AND
OPTIMA FAMILY CARE
(MEDICAID)**

PHARMACY PRIOR AUTHORIZATION/STEP-EDIT REQUEST*

Directions: The prescribing physician must sign and clearly print name (preprinted stamps not valid) on this request. All other information may be filled in by office staff; **fax to 1-800-750-9692.** No additional phone calls will be necessary if all information (including phone and fax #s) on this form is correct. **Incomplete form will delay authorization process.**

Drug Requested: Orkambi® (ivacaftor/lumacaftor)

RE-AUTHORIZATION FORM

DRUG INFORMATION: Complete information below or authorization process will be delayed.

Drug Form/Strength: _____

Dosing Schedule: _____ **Length of Therapy:** _____

Diagnosis: _____ **ICD Code, if applicable:** _____

Number of hospitalization (ICD 277-00-277.09) will be defined by ICD.

Orkambi® **will not** be covered for patients with FEV₁ ≥ 90 % initiation.

CLINICAL CRITERIA: Check applicable boxes below. To qualify, **all** boxes **must** be checked or authorization process will be delayed. **Must** attach **ALL** documentation/progress notes/lab results **AND** be compliant.

- Re-Approval will be based on **all THREE (3)** of the following:
 - Has the member Body weight increased at least 1.5kg? Yes **OR** No
 - Has the FEV₁ ≥ 5%? Yes **OR** No
 - Has hospitalization decrease since prior to Orkambi therapy? Yes **OR** No
 - Send Lab results documenting the following (**must be attached**):
 - Recent LFTs (within the last months)
 - Patient does not have positive cultures for Burkholderia cencopacia, Burkholderia dolosa, or Mycobacterium abscessus. **Lab documentation required within last six (6) months of THIS request.**
 - Member is currently **COMPLIANT** on **at least TWO (2)** of the following:
 - Dornase alfa
 - Hypertonic saline
 - Inhaled or oral antibiotics within the last 3 months

(continue on next page)

Baseline Date (PRIOR to Orkambi®): _____	Re-Authorization Date: _____
FEV1 Baseline (last FEV1 prior to Orkambi®): _____	FEV1 reauthorization (FEV1 AFTER last dose of Orkambi®): _____
Baseline Weight: _____	Re-Authorization Weight: _____
BMI baseline: _____	BMI Re-authorization: _____

Please note the number of hospitalization while on Orkambi® will be evaluated: . _____

While on Orkambi®, has IV/po antibiotics changed >3 times? Yes No

Medication being provided by a Specialty Pharmacy: Sentara Norfolk General CM Pharmacy

****Use of samples to initiate therapy does not meet step edit/ preauthorization criteria.****

Previous therapies will be verified through pharmacy paid claims or submitted chart notes.

Patient Name: _____

Member Optima #: _____ Date of Birth: _____

Prescriber Name: _____

Prescriber Signature: _____ Date: _____

Office Contact Name: _____

Phone Number: _____ Fax Number: _____

DEA OR NPI #: _____

***REVISED/UPDATED: 8/26/2017; 8/13/2018**